It might be thought that the flattening of COVID death curves might limit the value of future treatment options, but recent news suggests that this is not the case.
An article yesterday in The Scientist starts with this: Early reports from hospitals document a spike in large vessel blockages, especially among people in their 30s and 40s who tested positive for the coronavirus.
It is suspected that the virus may be causing inflammation of blood vessels, leading to blood clots. One report speculated that perhaps because young people don't suffer the respiratory issues that take a toll on older COVID-19 patients, they survive long enough for the virus to cause damage elsewhere.
A treatment that will address these issues is urgently needed. Failed trials suggest that targeting a single cytokine will not get the job done, so the Hudson Institute's discovery that IDX blocks STING at its source is a potentially valuable piece of IP as it implies that Veyonda has the ability to simultaneously block a wide range of cytokines.
If successful against COVID-19, FDA approval would enable Veyonda to be used to treat septic shock. There is much more to this story than appears obvious.
